Medicine & Life Sciences

1. Ovarian Neoplasms 100%
2. Poly(ADP-ribose) Polymerase Inhibitors 43%
3. Neoplasms 34%
4. veliparib 32%
5. Platinum 29%
6. Ovarian Epithelial Carcinoma 26%
7. gemcitabine 25%
8. Paclitaxel 23%
9. niraparib 21%
10. Drug Therapy 19%
11. Survival 16%
12. tanespimycin 16%
13. Heterografts 15%
14. Letrozole 14%
15. Therapeutics 13%
16. Somatomedin Receptors 13%
17. Triple Negative Breast Neoplasms 12%
18. rucaparib 11%
19. Homologous Recombination 11%
20. Progression-Free Survival 11%
21. Topotecan 11%
22. (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone 11%
23. BMS 536924 10%
24. OSI 027 10%
25. Mechanistic Target of Rapamycin Complex 2 10%
26. Group III Phospholipases A2 10%
27. AMG 479 10%
28. Mutation 10%
29. Carcinoma 10%
30. Estrogen Receptors 9%
31. MDX-H210 antibody 9%
32. Clinical Trials 9%
33. Nicotinamide N-Methyltransferase 9%
34. protein kinase C lambda 9%
35. ribociclib 9%
36. Fallopian Tubes 9%
37. Carboplatin 9%
38. Folate Receptor 1 8%
39. Puma 8%
40. Auranofin 8%
41. TOR Serine-Threonine Kinases 8%
42. Emergencies 8%
43. olaparib 8%
44. Placebos 8%
45. Epithelioid Hemangioendothelioma 7%
46. Loratadine 7%
47. Apoptosis 7%
48. Bevacizumab 7%
49. Bispecific Antibodies 7%
50. pembrolizumab 7%